BioSenic, a Belgian clinical-stage company specializing in serious autoimmune and inflammatory diseases and cell therapy, will share data on its late-clinical asset JTA-004 at the Osteoarthritis Research Society International (OARSI) World Congress 2024 in Vienna, Austria.
The post hoc analysis of a phase 3 study found that a single injection of JTA-004 was safe and efficacious for patients with a newly characterized severe inflammatory subtype of knee osteoarthritis (OA).
This week on the podcast, we talk about the treatment with BioSenic chief scientific officer and chief operating officer, Dr Carole Nicco.
00:52-03:19: About BioSenic
03:19-07:34: What is osteoarthritis?
07:34-11:45: What is ALLOB?
11:45-15:03: What is JTA-004?
15:04-17:14: What will you be presenting at the OARSI event?
17:14-20:20: How useful is attending events for BioSenic?
20:20-21:04: How often will JTA-004 need to be administered?
21:04-24:08: Are other companies working on osteoarthritis?
24:08-26:26: What stage are your arsenic trioxide trails at?
26:26-29:50: Will this be useful in treating other autoimmune diseases?
29:50-31:08: What are the next steps?
Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here!
Stay updated by subscribing to our newsletter
